The company is focused on the clinical development of a novel molecule for treating fragile X syndrome (FXS), a common cause of hereditary intellectual disability. This molecule has shown promising results in tests and animal models, and has the potential to treat other neurodevelopmental disorders such as Rett syndrome, Down syndrome, and autism spectrum disorders. CONNECTA Therapeutics aims to address unmet medical needs in the central nervous system by developing drugs that target neuroplasticity-mediated disorders.